Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline TP53m AML patients: Phase 1b results (Journal of Clinical Oncology, 2022)

(untitled) - Daver, NG; Vyas, P; Kambhampati, S; Al Malki, MM; Larson, RA; Asch, AS; Mannis, GN; Chai-Ho, W; Tanaka, TN; Bradley, TJ; Jeyakumar, D; Wang, ES; et al.